The IC Chat

Host Ashish Pershad examines the PVI‑SHAM‑AF sham‑controlled trial, explaining trial design, blinding, and endpoints for catheter ablation in symptomatic atrial fibrillation. The episode summarizes key results: ablation markedly reduced AF burden and recurrences but did not show superior quality‑of‑life improvement over an active sham at 6 months, highlighting a disconnect between objective rhythm control and patient‑reported symptoms. Practical takeaways discuss the role of sham controls when patient‑reported outcomes matter, enrollment challenges, and how these findings should inform shared decision‑making in interventional cardiology.

In this episode host Ashish Pershad reviews and critically appraises the REBOOT PARADOX randomized trial of TAVR versus optimal medical therapy in patients with paradoxical low‑flow, low‑gradient severe aortic stenosis. He summarizes trial design, patient selection, methods, and the challenges that led to early termination and underpowering. Key findings discussed include excellent hemodynamic relief after TAVR, a non‑significant difference in 2‑year all‑cause mortality, fewer heart‑failure hospitalizations with TAVR, high crossover from medical therapy, and persistence of low‑flow physiology—leading to the conclusion that close surveillance with selective intervention may be prudent until definitive trials are completed.

Host Ashish Pershad breaks down the AIR-STEMI (ARISTEMI) trial presented at ESC, explaining how physiology-guided (functional angiography) complete revascularization compares to angiography-guided approaches in STEMI patients with multivessel disease. He reviews study design, key results showing fewer events and safer outcomes with functional guidance, limitations, and practical takeaways for interventional cardiologists.

Host Ashish Prasad critically appraises two important interventional cardiology studies: a Taiwanese meta-analysis of four randomized trials comparing left atrial appendage occlusion to DOACs, and the ICARE randomized trial comparing intravascular lithotripsy (IVL) with rotational atherectomy for calcified coronary lesions. The meta-analysis found no overall difference in stroke but a non-significant trend toward higher ischemic stroke with LAA occlusion that became significant when the OPTION ablation study was excluded; LAA occlusion reduced non-procedural bleeding but procedural bleeds were omitted from safety endpoints. The ICARE trial showed IVL was non-inferior to rotational atherectomy for minimal stent area, with less stent malapposition and similar 12-month clinical outcomes, but was limited by surrogate endpoints, exclusion of balloon-uncrossable lesions, and small size. Takeaways: temper enthusiasm for broad LAA occlusion over DOACs and view IVL and atherectomy as complementary tools guided by imaging, lesion characteristics, and patient-specific risks.

In this episode of IC Chat, host Ashish Pershad reviews drug‑eluting balloons for coronary disease, appraising two landmark trials: AGENT‑IDE (in‑stent restenosis) and SOLUTION de novo (de novo lesions). He explains device pharmacology (paclitaxel vs. sirolimus), trial designs and results, practical considerations for vessel preparation and imaging, and offers cautious clinical takeaways about where drug‑eluting balloons may fit alongside drug‑eluting stents.